SecBot SecBot

DRUG

BRIGHT MINDS BIOSCIENCES INC.
Nasdaq· Pharmaceutical Preparations· Inc. A1· CIK 0001827401 Biotech & Drug Discovery
$51.09 −1.39 (−2.65%)
Oct 26 4:00 PM ET · prev $52.48
Market cap
$517.4M
Small cap
Consensus
Buy
86% Buy or better · 7 analysts
Median target
🔒 Subscribers only
1 year
−13.1%
from $58.78 · Oct 27
30 days
−1.1%
from $51.66
52-week range
$48.25–95.99
−47% from high · low Oct 6
Avg volume 20D
152.5K
Oct 7 spike 688.8K
Short interest
🔒 Subscribers only
Insider net
−$9.8M
0 buyers · 1 seller · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
3
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1
Strongest NEUTRAL Bright Minds Biosciences filed a Form 6-K reporting voting results from its annual general meeting held on…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • S Apr 28 1 insider sell $9.8M at $89.50
  • A Oct 15 Wolfe Research initiates

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $9.8M.

  • InstitutionsBULLISH

    Q2 2026: 17 added (1 new), 2 trimmed or exited. Largest new: Point72 Asset Management, $23.0M.

  • AnalystsBULLISH

    6 of 7 rate it Buy or better.

  • EstimatesRISING

    Current-quarter EPS estimate −$2.160 → −$1.450 over 90 days. 5 up, 1 down in 30 days.

  • TrendDOWNTREND

    17% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$23.0M
in new stakes
FundMoveSharesValue
ADAGE CAPITAL PARTNERS GP, L.L.C.TRIM335,000$23.5M
Point72 Asset Management, L.P.NEW327,416$23.0M
WELLINGTON MANAGEMENT GROUP LLPADD171,315$12.0M
GOLDMAN SACHS GROUP INCADD133,689$9.4M
VANGUARD PORTFOLIO MANAGEMENT LLCADD80,060$5.6M
Trexquant Investment LPDOUBLED70,615$5.0M
MILLENNIUM MANAGEMENT LLCADD66,740$4.7M
Schonfeld Strategic Advisors LLCDOUBLED66,277$4.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Buy 86% rate it Buy or better
Strong Buy3Buy3Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 15, 2026Wolfe Research
INITIATE
INITIATEOutperform
Aug 19, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 17, 2026BTIG
REITERATE
REITERATEBuy
Jun 1, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
May 20, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$9.8M
sold · 1 insider
DateInsiderTypeValue
Apr 28, 2026
Cormorant Asset Management, LP
SELL$9.8M

Earnings setup

Estimates
−$1.45
EPS estimate, this quarter
+33%
estimate change, 90 days
5↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.45-$2.12–-$0.61-8.9%$0.00
Next Q-$1.82-$2.72–-$1.21+1.0%$0.00
Current FY-$3.76-$4.47–-$2.85-3.2%$0.00
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 30, 2026
Press release
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a…
Sep 4, 2026
Press release
Bright Minds Biosciences to Present at Upcoming Conferences
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering…
May 26, 2026
Press release
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering…
Apr 8, 2026
Short interest
FTD: DRUG — 7,919 shares ($0.6M) failed to deliver
Settlement: 20260408, Price: $76.87, FTD Value: $608,733.53, BRIGHT MINDS BIOSCIENCES INC C

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 SEC
Bright Minds Biosciences filed a Form 6-K reporting voting results from its annual general meeting held on March 31…
6-K — Impact 2/10
Sep 30, 2026 Other
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG
Jun 30, 2026 Inst.
ADAGE CAPITAL PARTNERS GP, — TRIM
335,000 shares ($23.5M)
Jun 30, 2026 Inst.
Point72 Asset Management, L.P. — NEW
327,416 shares ($23.0M)
Jun 3, 2026 SEC
Bright Minds Biosciences filed its management information circular for the March 31, 2026 annual general meeting. The…
6-K — Impact 2/10
Jun 2, 2026 SEC
Bright Minds Biosciences Inc. filed a Form 6-K with the SEC on June 2, 2026, providing notice of its Annual General…
6-K — Impact 2/10
Apr 28, 2026 Insider
Cormorant Asset Management, LP sold 109,331 shares
$89.50 ($9.8M)

SecBot reports

3 filings · 0 bullish · 0 bearish · 3 neutral
All DRUG filing & press-release reports (3)